Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at StockNews.com

Sanofi (NASDAQ:SNY) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Several other research analysts have also commented on the company. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Up 1.1 %

Shares of NASDAQ SNY opened at $57.65 on Thursday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $55.04 and a two-hundred day simple moving average of $50.81. The firm has a market cap of $146.01 billion, a PE ratio of 28.97, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.95 EPS. Analysts expect that Sanofi will post 4.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SNY. Boston Partners grew its stake in Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after purchasing an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Mondrian Investment Partners LTD grew its stake in Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.